

Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC

<https://marketpublishers.com/r/T2E1570841AEN.html>

Date: June 2011

Pages: 2

Price: US\$ 140.00 (Single User License)

ID: T2E1570841AEN

Abstracts

Roche today announced results from the European EURTAC trial on Tarceva in EGFR+ve first line NSCLC patients. Tarceva improved Progression Free Survival (PFS) by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN's Iressa as it has not demonstrated OS benefit, despite showing good PFS benefit in the same population. Iressa is already approved in Europe in Jun 2009 for the treatment of all lines of EGFR positive advanced NSCLC.

Contents

COMPANIES MENTIONED

Roche, AstraZenica, Astellas, ROG, AZN, 4503

I would like to order

Product name: Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC

Product link: <https://marketpublishers.com/r/T2E1570841AEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T2E1570841AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970